Epilepsy is one of the most common neurological diseases and it causes profound morbidity and mortality.
Introduction
Genetic factors significantly contribute to the development of epilepsies, and >30% of all epileptic syndromes are considered to be of genetic origin [1] . The next-generation sequencing technology has expedited identification of new genes for epilepsies. These and previous genetic studies have resulted in development of several genetic tests that serve diagnostic purposes [1, 2] . However, variants in known genes may be responsible for only 30-50% of genetic epilepsies [1, 2] , whereas many additional genes potentially causing epilepsy remain undiscovered.
The KCNMA1 gene encodes the large conductance voltage-activated and Ca 2+ -activated potassium channel α-subunit (also referred to as BK channel, calcium-activated potassium channel subunit α1, MaxiK channel, KCa1.1, or Slo1). We previously reported a functional variant (c.1301 A > G (p.(D434G))) in the BK channel that causes a syndrome of combined generalized epilepsy and paroxysmal dyskinesia (GEPD) by markedly increasing the macroscopic potassium current and enhancing calcium sensitivity of the channel [3] . In this study, we identified a novel de novo variant (c.2984 A > G (p.(N995S))) in the BK channel that causes sole epilepsy in two independent families by employing a distinctly different mechanism from the c.1301 A > G (p.(D434G)) variant causing paroxysmal dyskinesia in addition to epilepsy. Our studies suggest that Xia Li, Sibylle Poschmann, Qiuyun Chen, and Walid Fazeli contributed equally to this work.
KCNMA1 should be considered as a new gene for epilepsy and thus be included into genetic epilepsy panels for genetic testing.
Materials and methods

Patients
This study involves five patients/families who were affected with epilepsy and had missense genomic variants identified in the KCNMA1 gene and reported to them. KCNMA1 variants were identified by whole-exome sequencing and targeted sequencing as previously described [4] [5] [6] . The patients sought genetic consultation from their genetic counselors or physicians, who in turn communicated with us for the functionality of KCNMA1 variants. Between January 2015 and April 2017, our laboratory received five referrals for consultation of the functionality of four variants identified in the KCNMA1 gene among the five independent patients with epilepsy. The variants and related phenotypic data can be found in the LOVD/shared database (www. LOVD.nl/KCNMA1, individual IDs 00132051-00132055). This study was approved by the Institutional Review Boards (IRB) on Human Subject Research at the Cleveland Clinic and the Ethics Committee on Human Subjects at Huazhong University of Science and Technology and other local IRBs. Written informed consent was obtained from the study subjects according to the IRB policies.
Plasmids and mutagenesis
The human KCNMA1 cDNA (GenBank accession number U23767) and KCNMB4 cDNA (GenBank accession number AF207992) were cloned into a mammalian expression vector pcDNA3.1, resulting in expression constructs KCNMA1-pcDNA3.1 and KCNMB4-pcDNA3.1 for the α-and β4-subunits of the BK channel, respectively.
Mutations were generated in KCNMA1-pcDNA3.1 using PCR-based site-directed mutagenesis and verified by direct DNA sequence analysis as described by us previously [3, 7] .
Cell culture and transfection
HEK293 cells were cultured in 24-well plates with DMEM supplemented with 10% fetal bovine serum at 37°C in an incubator with 5% CO 2 as previously reported [7] [8] [9] . These cells were co-transfected with a KCNMA1 expression construct and the pEGFP-N1 plasmid using Lipofectamine 2000 (Invitrogen) [7] [8] [9] . The transfected cells with a green EGFP signal were then selected for patch clamp recordings.
Patch clamp recording
Patch clamp recordings were carried out 6-24 h after the transfection as described by us and others [3, [7] [8] [9] . For single-channel recordings, the patches that contain only one channel were selected, and the recordings were digitized at 50 kHz and low-pass-filtered at 5 kHz [3, [8] [9] [10] . During the recording, solutions with different concentrations of calcium were applied onto the membrane patches via a perfusion pipette containing eight solution channels. The experiments were performed at room temperatures (22-25°C ). The data were collected from five to nine cells as described for patch-clamping of BK channels (n = 5-9) [8, 11] Recorded data were analyzed with Clampfit (Axon Instruments) and SigmaPlot (SPSS) software programs [3, [8] [9] [10] .
Statistical analysis
Two-tailed Student's t-test was used for comparing the means of two groups of variables. A P value of 0.05 or less was considered to be statistically significant.
Results
Identification of an identical de novo variant in KCNMA1 in two independent families with epilepsy Mutational analysis of the KCNMA1 gene (GenBank accession number NM_002247.3) identified a c.2984 A > G (p.(N995S)) variant in two independent patients with epilepsy. Both parents of the two patients were not affected by epilepsy (Fig. 1a) and did not carry this variant (Fig. 1a) . Sequencing data validated the paternal relationship. Therefore, the c.2984 A > G (p.(N995S)) variant occurred de novo in both patients.
The first epileptic patient was from the Netherlands, and presented with neonatal convulsions and a developmental delay. At the age of 9 years, she was diagnosed with primary generalized myoclonic absence epilepsy that was under control with levetiracetam. Seizures occurred only sporadically when the patient was tired. An EEG at the age of 17 years showed multifocal epileptic discharges. Brain MRI at the age of 17 years showed slight left-sided insular white matter abnormalities. At the age of 23 years, she had a short stature of 155 cm and small head circumference of 52.5 cm. She had no evident facial dysmorphic features. Neurological examinations revealed no paroxysmal dyskinesia or other obvious movement disorders.
The second patient was from Germany, and showed atypical absence epilepsy beginning at the age of 20 months. Semiology findings included arrest, mouth opening, head turning, variable altered consciousness and occasionally stronger seizures with risk of falls, duration of 10-20 s, and a frequency of >20 per day. At the age of 3 years, she developed additional myoclonic seizures, which occurred one to three times per day. No paroxysmal dyskinesia was found. She was a couple of days seizure-free during varicella-zoster and Streptococcus pyogenes infection. Her psychomotor development was mildly delayed. MRI scan and metabolic tests showed normal results. Her EEG showed generalized spike waves located centrally and frontally, and photosensibility. Antiepileptic treatment with ethosuximide led to significant worsening of seizures, and oxcarbazepine and valproate showed negative effects. Sultiame and perampanel did not influence the seizures, either. Zonisamide alone reduced the seizure frequency, but did not stop the myoclonic seizures. Levetiracetam reduced the seizure frequency and stopped myoclonic seizures. She is currently treated with levetiracetam alone.
The c.2984 A > G (p.(N995S)) variant involves an amino-acid residue, which is highly conserved among different species during evolution (Fig. 1b) . Moreover, this variant occurs within the second Ca 2+ -responsive RCK domain (Fig. 1c) . The c.2984 A > G (p.(N995S)) variant does not exist in the public databases (ExAC, GNOMAD, 1KGP, and NHLBI ESP; Table 1 ). Identification of the same de novo variant in two independent, unrelated families provides the strongest genetic evidence that the c.2984 A > G (p.(N995S)) variant causes epilepsy shared by the two families.
The p.(N995S) variant markedly increases the macroscopic potassium current of the BK channel
To determine whether the c.2984 A > G (p.(N995S)) variant has a functional effect on BK channels, we overexpressed the mutant p.(N995S) channel and control wild-type (WT) channel in HEK293 cells, recorded the potassium currents, and analyzed the current-voltage relationship. At an intracellular calcium concentration of 10 μM, the p.(N995S) variant markedly increased the activation rate ( Fig. 1e) and caused a large shift of the G-V curve to the negative potentials by 59 mV (n = 6, P < 0.05; Fig. 1f ). These data suggest that the p.(N995S) mutant BK channel opens more easily and faster than the WT channel and that the mutant channel generates a greater macroscopic BK current at a given calcium concentration and a membrane potential than its WT counterpart.
Because the above data indicate that the p.(N995S) variant appears to be a gain-of-function variant, which significantly increases the BK current, BK channel inhibitors may block the BK potassium current and treat epilepsy. We examined the effect of paxilline, a selective BK channel blocker [12] , on the potassium currents generated by WT and p. Because the β4 subunit of the BK channel is the subunit predominantly expressed in the central nervous system [13, 14] , we studied the effect of the epilepsy-linked p.(N995S) variant on the BK channel in the presence of the β4 subunit and characterized the current-voltage relationship of the WT and mutant BK channels in the presence of the β4 subunit. The p.(N995S) variant markedly enhanced the activation of BK channels ( Fig. 2a) and shifted the G-V curve to a negative potential by 71 mV (n = 6, P < 0.05; Fig. 2b ) in the presence of the β4 subunit at a calcium concentration of 10 μM.
The p.(N995S) variant does not affect the calcium sensitivity of the BK channel
We recorded the currents from WT and mutant BK channels under a series of calcium concentrations, including nominal 0, 1, and 10 μM (Fig. 3a) . The V 1/2 values differed between the p.(N995S) mutant and WT channels at all three calcium concentrations (Fig. 3b) . Similarly, the absolute values of ΔV 1/2 (V 1/2 (p.(N995S)) -V 1/2 (WT)) for the p.(N995S) mutant and WT channels were >40 mV at all three calcium concentrations (n = 6, P < 0.05; Fig. 3c ). However, the differences for the V 1/2 values between the p.(N995S) mutant and WT channels remained similar independent from the calcium concentrations (Fig. 3c) , suggesting that the p.(N995S) variant increases BK channel activation without enhancing calcium sensitivity. Moreover, the p. (N995S) mutant channel remained highly activated even at a nominal calcium concentration of 0 μM (Figs. 3a, b) . D963N) ). The p.(N995S) mutant channels continued to generate greater macroscopic potassium currents compared to WT channels even when the two calciumbinding sites were mutated. Moreover, the G-V curves of the p.(N995S) mutant channel were still shifted to negative potentials by more than 40 mV at nominal calcium concentrations of 0, 1, and 10 μM without a change of the slope as compared to the WT channel (Fig. 3d ). The differences of the V 1/2 values between the p.(N995S) mutant channels and the WT channels were identical at nominal 0, 1, and 10 μM of calcium (Fig. 3e) (Fig. 4a) . The single-channel conductance of the WT and mutant channels were 268.5 ± 13.2 (pS) and 276.3 ± 18.9 (pS), respectively (Fig. 4a) . There is no statistically significant difference between the WT and mutant channels for the single-channel conductance (n = 9, P > 0.05), which indicates that the p.(N995S) variant does not affect the pore structure of the BK channel. The P o -V curve of the p. (N995S) mutant channels shifted to negative potentials at both 1 μM Ca 2+ and 10 μM Ca 2+ compared with the WT BK channels (Fig. 4b) , which is consistent with the data from the macroscopic current recordings (Fig. 1) . The distribution of the open dwell time was different between the WT channels and the mutant channels. The open dwell time histograms were fitted by an exponential function, and the . All G-V curves are fitted by Boltzmann function (solid lines) with V 1/2 at nominal 0 μM Ca 2+ (158.2 ± 6.3 mV for WT and 115.8 ± 6.9 mV for p.(N995S), P < 0.05), at 1 μM Ca 2+ (102.8 ± 2.6 mV for WT and 15.8 ± 3.5 mV for p. (N995S), P < 0.05), and at 10 μM Ca 2+ (14.1 ± 6.6 mV for WT and −44.6 ± 8.2 mV for p.(N995S), P < 0.05). c V 1/2 of G-V curves vs. The data are presented as mean ± SD (n = 6, P < 0.05) time constant of the mutant channels was found to be larger than that of WT channels at the same potentials and calcium concentrations (n = 5, P < 0.05; Figs. 4c, d ). This suggests that the mutant channels remain open for a longer period compared with WT channels. The open state of the mutant channels appears to be more stable than WT channels. Thus, the single-channel analysis identified the mechanism by which the p.(N995S) variant enhances BK macroscopic currents to be the increased single-channel open probability and increased open dwell time.
Identification and characterization of three other genomic variants in KCNMA1
Whole-exome sequencing analysis identified three other genomic variants in KCNMA1 in three other patients with epilepsy, i.e., c. Figure S3a and b) . The c.3476 A > G (p.(N1159S)) variant was found in the ExAC, GNOMAD, and 1KGP databases, whereas the other two variants were found in the GNOMAD database ( Table 1 (1.9 ± 0.5 ms for WT and 3.9 ± 1.1 ms for p.(N995S), P < 0.05) and at 10 μM Ca 2+ (2.8 ± 0.5 ms for WT and 4.9 ± 1.1 ms for p.(N995S), P < 0.05). The data are presented as mean ± SD (n = 5, P < 0.05) (K518N)) variant did not want to be tested genetically; thus, we could not determine whether the variant occurred de novo. No differences were observed between the three mutant channels and WT channels with regard to the activation and current density of the BK channels in the presence or absence of the β4 subunit ( Supplementary  Figures S1-S3 ). These data suggest that the three variants are not likely to affect the function of BK channels, and instead may represent benign genetic variants.
Discussion
Our data in the present study demonstrate that variants in the large conductance calcium-sensitive potassium BK channel can cause epilepsy. This conclusion is strongly supported by both genetic and electrophysiological studies. We have identified a novel molecular mechanism by which a variant in the KCNMA1 gene can cause epilepsy. The p.(N995S) variant leads to a significant increase of the macroscopic potassium current of the BK channel by shortening the channel activation time and markedly shifting the G-V curve to negative potentials by 59 mV at 10 μM Ca 2+ (Fig. 1) . The p.(N995S) variant can enhance the BK current by increasing the open probability and significantly prolonging the channel open dwell time without enhancing calcium sensitivity (Figs. 2 and 3) .
The c.1301 A > G (p.(D434G)) variant in KCNMA1 causes a phenotype characterized by the co-existence of GEPD [3] , whereas the c.2984 A > G (p.(N995S)) variant in this study causes epilepsy only. We found that the functional effects of the p.(D434G) and p.(N995S) variants are distinctly different. The p.(D434G) variant affects both the voltage activation pathway and the calcium-dependent activation pathway; however, the p.(N995S) variant does not affect the calcium sensitivity. These data suggest that the calcium-activation pathway of the BK channel may be associated with paroxysmal dyskinesia, but not with epilepsy. However, the underlying molecular mechanism is not clear. We have shown that the changes of intracellular calcium concentrations have significant effects on mutant BK channels with the p.(D434G) variant associated with paroxysmal dyskinesia [3] . The release of calcium ions out of the sarcoplasmic reticulum that occurs during contraction of muscles may affect the activity of mutant BK channels with the p.(D434G) variant, potentially leading to paroxysmal dyskinesia. However, mutant BK channels with the p. (N995S) variant are insensitive to the changes of intracellular calcium concentrations during contraction of muscles and, therefore, do not increase the risk of paroxysmal dyskinesia.
It is interesting to note that there are phenotypic differences between the two female patients carrying the same c.2984 A > G (p.(N995S)) variant. The age of onset was 9 years for the patient from the Netherlands, but 20 months for the patient from Germany. The epilepsy for the patient from the Netherlands was primary generalized myoclonic absence epilepsy, but was atypical absence epilepsy for the patient from Germany. The difficulties in assessing genotype-phenotype correlations in genetic epilepsies is well known, and unfortunately poorly understood. For example, the identical variant in SCN2A encoding for the voltage-gated sodium channel Na V 1.2 was associated with a broad spectrum of epilepsies [15] . Recently, a large-scale comparison between two C. elegans isolates suggested that differences in the manifestation of mutant phenotypes between individuals are largely the result of natural variation in gene expression [16] . In our cases, potential mechanisms underlying the different phenotypes between the two patients carrying the same c.2984 A > G (p. (N995S)) variant may be related to genetic modifiers (i.e., variants in other genes), environmental/exogenous factors, and/or natural variation in gene expression.
Of note, levetiracetam was effective against epileptic seizures in both patients with the c.2984 A > G (p.(N995S)) variant. Levetiracetam was shown to inhibit presynaptic calcium channels [17] [18] [19] , but our data suggest that the c.2984 A > G (p.(N995S)) variant causes epilepsy without affecting the calcium-activation pathway of BK channels. Thus, the underlying mechanism for the efficacy of levetiracetam is an interesting topic to be further investigated in the future. Moreover, because we found that the increased BK current is a cause of epilepsy, BK channel inhibitors or blockers may be a novel strategy for the treatment of epilepsy. In line with this, intraperitoneal injection of the BK channel blocker paxilline eliminated tonic-clonic seizures and reduced seizure duration and intensity, which were induced in rats by injection of the gamma-aminobutyric acid (A) antagonists picrotoxin or pentylenetetrazole [20] . We found that treatment with 200 nM paxilline markedly reduced the potassium currents from both WT BK channels and p.(N995S) mutant BK channels (Figs. 1g, h, i) . Some residual potassium current was still present in p.(N995S) mutant BK channels at the specific paxilline concentration (Figs. 1g, h, i) , which may be beneficial because a complete abolition of the BK current is too toxic for treatment. It is possible to identify a dose of paxilline that may block the BK current from mutant channels to a physiological level, which may be used to treat epilepsy. Future effort can also target the BK channel to develop specific inhibitors or blockers of the mutant BK channel activity suitable for the treatment of human patients with epilepsy.
The molecular mechanism by which variant c.2984 A > G (p.(N995S)) affects the function of the BK channel remains to be identified. On the basis of the crystal structure of the cytoplasmic domain of the BK channel [21, 22] , the p.N995 residue is located within the "turn" in the helix-turnhelix connector for the "flexible interface" that connects the RCK1 and RCK2 domains. The amino-acid residues in the helix are important for the calcium-dependent activation of the BK channel [21, 22] . The p.N995 residue is in the turn of the helix-turn-helix connector (i.e., not in the helix); thus, it is not involved in the calcium-dependent activation of the BK channel. On the other hand, the turn of the helix-turnhelix connector may be important for the overall molecular conformation of the BK channel through strengthening the interaction between the two RCK domains and other parts of the channel. The c.2984 A > G (p.(N995S)) variant may alter the overall molecular conformation of the BK channel, weakening the closed state, or stabilizing the open state of the channel to make it open more frequently and for a longer period of time (Fig. 4) .
In the era of precision medicine, the data in our study clearly demonstrate the critical importance of functional characterization of genomic variants of unknown significance identified by whole-genome sequencing or wholeexome sequencing. In this study, we identified four genomic variants in the BK channel in patients with epilepsy. Yet, c. There is one limitation in our study. Our patch-clamping studies were carried out at room temperatures of 22-25°C; therefore, we cannot exclude the possibility that variants c.1554 G > T (p. (K518N) ), c.1967A > C (p.(E656A)), and c.3476 A > G (p.(N1159S)) may have an effect on the BK channel at a more physiological temperature of 37°C.
In summary, our data demonstrate that variants in the BK channel α-subunit cause epilepsy. Our study identifies the first de novo variant in the BK channel α-subunit causing epilepsy. We have shown that the molecular mechanism for BK channel-associated epilepsy involves the allosteric voltage gating, but not the calcium-dependent activation of the channel. We further show that electrophysiological characterization is required to determine whether a BK channel variant is causative to disease. We suggest that the BK channel is a novel potential target for the development of treatments for epilepsy.
